Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Frequently asked questions
What sector does Evogene Ltd (EVGN) operate in?
Evogene Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Evogene Ltd (EVGN) current stock price?
As of the latest data, Evogene Ltd stock price is $0.60, with a previous close of $0.69. Evogene Ltd lost -$0.09 in the last trading session, representing a -12.41% loss.
What is Evogene Ltd (EVGN) current market capitalization?
Evogene Ltd market cap is approximately 7.26 million.
What is Evogene Ltd (EVGN) Earnings Per Share (EPS)?
The trailing EPS is -$1.67, and the forward EPS is -$0.80.
What is Evogene Ltd (EVGN) EBITDA?
Evogene Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.82 million.
Does Evogene Ltd (EVGN) pay dividends?
No. Evogene Ltd does not pay a dividend.
How did Evogene Ltd (EVGN) perform in its most recent earnings report?
In the last report (March 31, 2026), Evogene Ltd posted an EPS surprise of -125.74% and a revenue surprise of -4.57%.
When is Evogene Ltd (EVGN) next earnings report?
Evogene Ltd is expected to release its next earnings report on June 30, 2026.
What is Evogene Ltd (EVGN) beta (volatility) score?
Evogene Ltd has a beta of 0.776, indicating lower volatility than the overall market.
